Axbio Showcases Cutting-Edge Diagnostic Innovations at the 2024 Riyadh Global Medical Biotechnology Summit

Riyadh, Saudi Arabia – November 12, 2024 - Axbio Inc. had tremendous success at the 2024 Riyadh Global Medical Biotechnology Summit (RGMBS), a prestigious event organized by the Ministry of National Guard Health Affairs in collaboration with the Ministry of Investment Saudi Arabia (MISA). The summit provided a platform to discuss the latest advancements in medical biotechnology, bringing together key industry leaders, including AstraZeneca and the United Drug Promotion Association, to foster global collaboration in the biotech and pharmaceutical sectors.

Dr. Tian Hui, Founder and CEO, and Dr. Nikolay Sergeev, Vice President of Applications, attended as VIP guests and invited speakers. They presented Axbio's molecular testing and multi-omics platforms, designed to address the diverse scientific research and clinical needs of the Middle East.

During his speech, Dr. Sergeev highlighted the advantages of Axbio's fourth-generation nanopore sequencing technology and its critical role in managing hereditary diseases in alignment with the Saudi Human Genome Program (SHGP) and Saudi Vision 2030 national healthcare objectives. He showcased key applications of the Axilona AXP-100 platform for genetic analysis, infectious disease diagnostics, and environmental monitoring. Additionally, he introduced the AxiLona EL-100 microarray platform for rapid molecular testing and Axbio's saliva glucose monitor for at-home testing, which can aid in diabetes prevention and management.

To strengthen regional engagement, the Axbio team visited key institutions, including the Saudi FDA, King Abdullah International Medical Research Center (KAIMRC), the Ministry of Investment (MISA), and All Care Group, to discuss regulatory frameworks and collaboration opportunities.

Axbio stays committed to advancing clinical diagnostics and healthcare worldwide through continuous innovation in diagnostic solutions.

For more information about Axbio's multi-omics diagnostics platforms, visit www.axbio.com.